Enterprise Value

-481.1K

Cash

15.39M

Avg Qtr Burn

-15.35M

Short % of Float

0.51%

Insider Ownership

25.54%

Institutional Own.

9.30%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MB-107 Details
X-Linked severe combined immunodeficiency

Phase 2

Initiation

MB-207 Details
X-Linked severe combined immunodeficiency, Myelofibrosis

Phase 2

Initiation

MB-110 (LV-RAG1) Details
Severe combined immunodeficiency due to complete RAG1/2 deficiency

Phase 1/2

Data readout

MB-106 (CD20) (Mustang Multicenter) Details
Non-Hodgkin lymphoma, Cancer, Lymphoma, Chronic lymphocytic leukemia

Phase 1/2

Data readout

MB-106 (CD20) (Fred Hutch) Details
Non-Hodgkin lymphoma, Lymphoma, Chronic lymphocytic leukemia, Multiple sclerosis, Epstein-Barr virus, Cancer, Waldenstrom macroglobulinemia

Phase 1/2

Update

MB-105 (PSCA) Details
Prostate cancer, Multiple myeloma, Cancer

Phase 1

Data readout

MB-104 Details
Multiple myeloma, Solid tumor/s, Cancer

Phase 1

Data readout

MB-103 (HER2) Details
Glioblastoma, Metastatic breast cancer to brain, Cancer

Phase 1

Data readout

MB-101 (IL-13Ra2) + MB-108 Details
Glioblastoma, Ependymoma, Medulloblastoma, Leptomeningeal brain tumors

Phase 1

Update

MB-102 (CD123) Details
High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer

Failed

Discontinued